BioInnovation Institute’s Post

Telomir Pharmaceuticals, Inc., a pre-clinical pharma company, has garnered attention for its leading drug compound, Telomir-1, designed to regenerate telomeres – the protective DNA structures at the ends of chromosomes. In a recent ABC television news segment, two senior dogs, Zeus and Benson, exhibited remarkable improvements after being treated with Telomir-1. 'Zeus, a 12-year-old German Shepherd, showed complete remission of terminal cancer, while Benson, a 12-year-old Newfoundland suffering from severe arthritis, regained his mobility, leading to what caretakers described as a miraculous recovery,' reported Telomir. 'The results of this study highlight the groundbreaking potential of Telomir-1,' said Erez Aminov, CEO of Telomir. 'Our priority is to advance the rigorous scientific research required to bring this promising treatment to humans and pets.' By lengthening telomeres, Telomir-1 aims to promote cell regeneration and potentially reverse aspects of aging or age-related conditions. With encouraging results from the dog study and more tests underway, Telomir Pharmaceuticals could be a company to watch in the quest to reverse time. #longevity #agereversal #telomeres #pharmaceuticals #doghealth

𝐀𝐬𝐭𝐫𝐚𝐙𝐞𝐧𝐞𝐜𝐚 𝐭𝐨 𝐚𝐜𝐪𝐮𝐢𝐫𝐞 𝐀𝐦𝐨𝐥𝐲𝐭 𝐏𝐡𝐚𝐫𝐦𝐚, 𝐞𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐥𝐚𝐭𝐞-𝐬𝐭𝐚𝐠𝐞 𝐫𝐚𝐫𝐞 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐩𝐢𝐩𝐞𝐥𝐢𝐧𝐞 AstraZeneca AstraZeneca announced its agreement to acquire Amolyt Pharma Amolyt Pharma, a biotech company focused on rare endocrine diseases. The acquisition includes eneboparatide (AZP-3601), a Phase III investigational therapy for hypoparathyroidism. Hypoparathyroidism, characterized by a deficiency in parathyroid hormone (PTH), affects around 115,000 people in the US and 107,000 in the EU, predominantly women. Eneboparatide aims to address this unmet need. Key Points: Eneboparatide normalizes serum calcium levels and reduces dependency on calcium supplements. Phase II data show promising results, including the preservation of bone mineral density. The acquisition cost totals $1.05 billion, including an $800 million upfront payment and a potential $250 million contingent payment. The transaction is expected to close by the end of the third quarter of 2024, pending regulatory approvals. #RareDisease #Hypoparathyroidism #Biotech #PharmaAcquisition #RareEndocrinology #PipelineExpansion #ClinicalResearch

So here is the deal with the newly approved MASH drug… 💊 MASH (Metabolic Associated Steatohepatitis) is a new therapeutic indication that is making waves in the world of biopharma. This condition, a more severe form of non-alcoholic fatty liver disease, has been a focus of several biotech companies, including Chinese biotech firm, Madrigal Pharmaceuticals. 💡 Madrigal has recently celebrated a Phase 2 victory with their MASH drug, resmetirom, which has shown promising results in reducing liver fat and inflammation. This is a significant step forward, as there are currently no FDA-approved drugs specifically for MASH. 🚀 The FDA has now given the green light for the first MASH drug, marking a major milestone in the treatment of this disease. This approval not only validates the potential of MASH therapies but also paves the way for future advancements in this area. 🔍 Meanwhile, NeuroBo Pharmaceuticals, Inc. is also making strides in this field, with a clinical trial underway for their own MASH treatment. #biopharma #drugdevelopment #MASH #innovation #founditonzymewire

Eli Lilly and Novo Nordisk are thriving in the weight-loss market with popular drugs like Wegovy and Ozempic. For investors seeking smaller opportunities, Altimmune (NASDAQ: ALT) is developing pemvidutide, a glucagon-like peptide 1 (GLP-1) agonist showing promising results in clinical trials. Key Insights - ▪️ Weight-Loss Success - Patients on pemvidutide lost an average of 15.6% of their weight over 48 weeks. ▪️ Potential Beyond Weight Loss - The drug might also treat metabolic dysfunction-associated steatohepatitis (MASH), a type of liver disease. ▪️ Company Risks - With a market cap of $570 million, Altimmune is smaller and riskier, facing net losses and potential stock dilution as it lacks approved products. Discussion Points - ▪️ What impact could pemvidutide have on the weight-loss market if approved? ▪️ How can Altimmune manage its cash burn rate while developing a sustainable revenue stream? #Biotech #WeightLoss #Investing #GLP1Drugs

Biotech is not all roses, as we know too well. Recently, a huge disappointment came when Amylyx Pharmaceuticals announced that their drug Relyvrio/Albrioza did not meet any of the endpoints in the phase 3 study against ALS (amyotrophic lateral sclerosis). This was a blow both for the company and the ALS community, which has very few treatment options. The drug is a combination of two well-known compounds, and it showed limited efficacy in a phase 2 trial. The FDA first rejected the drug, but when the company performed additional analysis, and after some pressure from the ALS community it received conditional approval in 2022. The price was set to $158 000. Many people were optimistic back then about the prospects of the drug, but the harsh reality of biotech hit hard. It is not unusual for any drug to show some efficacy in phase 2 and then to fail in phase 3. What is more unusual, is that the company decided to pull the drug off the market immediately, and everyone should give them credit for that. In some aspect, this decision contradicts the fiduciary duty of management to shareholders. However, it is the only right decision from the ethical standpoint, as the patients should not pay for the drug that doesn’t work and should not be given false hopes. Amylyx decision clearly demonstrates that at least some biopharma companies are able to put patients’ interests above the financial ones, which is good for the perception of biotech by the public. In our fund, we don’t invest in reformulations (although there are successful cases, cf. Karuna Therapeutics), and are very cautious about the neurodegenerative space in general (I have a personal experience developing a drug against ALS, and it didn’t play well). So we wouldn’t invest in Amylyx in any case, but we closely watch the field and try to learn from other’s failures.   #ALS #DrugDevelopment #FDA

🌟 The orphan drug sector, once a rising star in the pharma industry, is facing challenges ahead! 🚀 Despite fierce competition and pricing pressures, the market for rare disease drugs is still on the rise. 💊📈 🔝 In 2028, brace yourself for the top 10 most valuable orphan drugs making waves with a whopping $57 billion! 💰 Leading the pack are Johnson & Johnson's Darzalex, Vertex's Trikafta, and Roche's Hemlibra. 🏆 Exciting new players like Incyte and Novartis' Jakafi, as well as J&J's Carvykti, are making their mark too. 🌟 And let's not forget about Amgen's game-changing move with the acquisition of Horizon Therapeutics! 🌟 💡 The future of rare disease treatments is evolving, and these key players are at the forefront of innovation and impact. 🌍💊 #PharmaIndustry #OrphanDrugs #Innovation #HealthcareRevolution

Uncovering Hidden Costs in nAMD Clinics In the quest for cost-effectiveness, are we missing a crucial piece of the puzzle? Our latest publication "Real-world service costs for neovascular-AMD clinics in the United Kingdom: Structured literature review and scenario analysis" published in Current Medical Research and Opinion, reveals the significant strain costs impacting nAMD clinics, often overlooked in traditional cost-effectiveness analyses. In our scenario analysis, Drug A may appear cheaper with a lower upfront cost (£10), the associated strain costs (£13,115) paint a different picture compared to Drug B (£100 upfront with no additional strain costs). What does this mean? • Drug A: Lower initial cost but significant long-term strain costs. • Drug B: Higher initial cost but no additional strain costs. Impact on decision-making: When evaluating options, it's essential to consider not just the drug costs, but also the broader economic impact on the service as a whole. Incorporating strain costs into Health Technology Assessments (HTA) provides a more comprehensive view, ensuring sustainable and efficient healthcare delivery. Read the full article to explore our findings and methodology in detail: https://lnkd.in/d2-gjXba Get in touch with Medialis Ltd at info@medialis.co.uk to help shift your focus to more holistic evaluations that account for all costs, fostering better decision-making and improved patient care. Join the conversation and share your insights on how we can better integrate these findings into our practices. #nAMD #HealthcareEconomics #CostEffectiveness #HTA #HealthcareInnovation #nASInstrument #DiseaseSpecific AEterna Zentaris Inc., Alexion Pharmaceuticals, Inc., Antengene, Apollomics, Arena Pharmaceuticals, Inc., argenx, Astellas Pharma, Avadel Inc., Avadel Pharmaceuticals PLC, Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CorestemChemon Inc., CSL Behring B.V., Cumberland Pharmaceuticals , CymaBay Therapeutics, EMD Serono, Inc., Italfarmaco, Kite Pharma, ML Bio Solutions, Moderna, MultiVir, Inc., OPKO Health, Inc., Ra Pharmaceuticals, Revolo Biotherapeutics , 德琪医药Antengene, SK Life Science, Inc., Strata Oncology, Syros Pharmaceuticals, Arterys (Acquired by Tempus Labs)

This week's Pearce IP #BioBlast features the following (and more!):    - #pembrolizumab: Phase 3 supports MSD’s #Keytruda® combo for gastric cancer - #adalimumab: Quallent Pharmaceuticals Health, LLC to distribute Alvotech’s high concentration interchangeable #adalimumab in US as private label medicine - #adalimumab: FDA approves Boehringer Ingelheim’s high-concentration, citrate-free #Humira® biosimilar - #trastuzumab: First US biosimilar approval for Accord BioPharma’s #trastuzumab - #denosumab: Sandoz and Amgen resolve US #denosumab biosimilar dispute; launch from 31 May 2025 - Samsung Bioepis Reports Year Over Year Revenue Growth of 31% - #etanercept: Lupin & Sandoz launch #Rymti® (#etanercept) biosimilar in Canada Read more: https://lnkd.in/dQzCaYvk   #BioBlast #biosimilars #boutiquelawfirm #australia #patentlaw #awardwinning #pearceip #patents #biopharma #lifesciences #femalefounder 

Sales at ex-factory prices in the Swiss pharmaceutical market rose by 4.9% According to a recent press release by vips Vereinigung Pharmafirmen in der Schweiz and Interpharma in collaboration with IQVIA, the Swiss pharmaceutical market saw a 4.9% increase in sales in 2023, reaching 7.4 billion Swiss francs despite a curbing effect of 2.7% due to price cuts. Key growth areas included oncology, autoimmune diseases and antivirals, reflecting the sector’s commitment to innovation. Generics and biosimilars also recorded significant growth, underscoring the market’s adaptability. The Swiss pharma market, known for its robust growth, is a hub for innovative drugs and treatment methods, making it a leading center for healthcare advancements. We make it our mission to help biotechnology companies thrive in this market and combine economic success with health improvements. Visit our blog for more insights and graphics on this topic: https://lnkd.in/dAHbrjdG #SwizzardPharma #HealthcareInnovation #MarketGrowth Michael Zürcher, PhD EMBA | Bettina Schelbert | Karin Senn